Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys targets lowered. See how others view these stocks.
Stocks · News reference
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $25 to $30.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Generate Biomedicines, Inc. (GENB)
Filed: 2026-08-26 AccNo: 0001193125-26-365556 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Generate Biomedicines shares are trading lower after the company reported mixed Q2 financial results.